VivoSim Labs (NASDAQ:VIVS) Announces Earnings Results

VivoSim Labs (NASDAQ:VIVS) posted its quarterly earnings data on Tuesday. The company reported ($2.21) EPS for the quarter, FiscalAI reports. The business had revenue of $0.04 million during the quarter. VivoSim Labs had a negative return on equity of 15.51% and a negative net margin of 861.27%.

VivoSim Labs Stock Performance

NASDAQ:VIVS opened at $0.83 on Wednesday. The company has a 50-day moving average of $1.17 and a 200-day moving average of $1.61. VivoSim Labs has a 52 week low of $0.78 and a 52 week high of $5.30. The company has a market capitalization of $2.18 million, a price-to-earnings ratio of -0.27 and a beta of 1.40.

Institutional Trading of VivoSim Labs

An institutional investor recently bought a new stake in VivoSim Labs stock. Two Sigma Investments LP purchased a new position in shares of VivoSim Labs, Inc. (NASDAQ:VIVS) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 23,192 shares of the company’s stock, valued at approximately $68,000. Two Sigma Investments LP owned 0.89% of VivoSim Labs as of its most recent SEC filing. 8.23% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings cut shares of VivoSim Labs from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, May 22nd. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock has a consensus rating of “Sell”.

VivoSim Labs Company Profile

VivoSim Labs, Inc (NASDAQ: VIVS) is a biotechnology company specializing in the development and commercialization of advanced 3D human tissue models for preclinical drug testing and disease modeling. The company’s proprietary organoid platforms and cell-based assays are designed to replicate human physiological environments, enabling more predictive evaluation of drug efficacy, safety, and toxicity before clinical trials. By integrating cutting-edge bioengineering and microfluidics technologies, VivoSim Labs seeks to bridge the gap between traditional cell culture methods and human clinical outcomes.

The company’s product portfolio includes 3D bioprinted tissues, organ-on-a-chip systems, and disease-specific models targeting key therapeutic areas such as oncology, cardiology, and hepatology.